Literature DB >> 19008986

Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term.

Kathleen Costello1, Patricia Kennedy, Jo Scanzillo.   

Abstract

CONTEXT: Patients with multiple sclerosis (MS) face many challenges. One significant challenge is long-term adherence to disease-modifying therapy (DMT). Four of the 6 currently available DMTs involve self-injection, and all cause adverse events of varying degrees of severity. Although effective, the benefit of DMTs is difficult to determine on an immediate basis. Healthcare providers must play a major role in recognizing nonadherence and identifying strategies to promote adherence. EVIDENCE ACQUISITION: We conducted a literature search of the MEDLINE database using the search terms "adherence" and "multiple sclerosis" to gather data from relevant studies investigating adherence among patients with MS. EVIDENCE SYNTHESIS: Barriers to maintaining treatment adherence in patients with MS include forgetting the medication, injection anxiety, perceived lack of efficacy, coping with adverse events, and issues with complacency and treatment fatigue. An open and honest healthcare provider-patient relationship is a core element in maintaining motivation and adherence in patients with MS. In addition, continuous education and consistent reinforcement of the value of treatment are essential strategies in the maintenance of treatment adherence. Other strategies to promote adherence include management of treatment expectations and minimization of adverse events.
CONCLUSIONS: The chronic nature of MS makes treatment adherence challenging in patients with long-standing disease. Patients and healthcare providers need to work together to establish open lines of communication and a trust-based therapeutic relationship to ensure that patients have the knowledge and skills they need to adhere to long-term MS therapy.

Entities:  

Mesh:

Year:  2008        PMID: 19008986      PMCID: PMC2580090     

Source DB:  PubMed          Journal:  Medscape J Med        ISSN: 1934-1997


  19 in total

Review 1.  Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

Authors:  Helen L Tremlett; Joel Oger
Journal:  Neurology       Date:  2003-08-26       Impact factor: 9.910

Review 2.  Adherence to interferon-beta treatment and results of therapy switching.

Authors:  Marinella Clerico; Pierangelo Barbero; Giulia Contessa; Cinzia Ferrero; Luca Durelli
Journal:  J Neurol Sci       Date:  2007-03-21       Impact factor: 3.181

3.  Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis.

Authors:  C Fraser; O Hadjimichael; T Vollmer
Journal:  J Neurosci Nurs       Date:  2001-10       Impact factor: 1.230

4.  Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis.

Authors:  Darcy Cox; Jerome Stone
Journal:  J Neurosci Nurs       Date:  2006-06       Impact factor: 1.230

5.  Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis.

Authors:  Jordi Río; Joana Porcel; Nieves Téllez; Angela Sánchez-Betancourt; Mar Tintoré; M Jesús Arévalo; Carlos Nos; Xavier Montalban
Journal:  Mult Scler       Date:  2005-06       Impact factor: 6.312

6.  Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone).

Authors:  J Haas; M Firzlaff
Journal:  Eur J Neurol       Date:  2005-06       Impact factor: 6.089

7.  Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject.

Authors:  D C Mohr; A C Boudewyn; W Likosky; E Levine; D E Goodkin
Journal:  Ann Behav Med       Date:  2001

8.  Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis.

Authors:  Cira Fraser; Olympia Hadjimichael; Timothy Vollmer
Journal:  J Neurosci Nurs       Date:  2003-06       Impact factor: 1.230

9.  Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model.

Authors:  A P Turner; D R Kivlahan; A P Sloan; J K Haselkorn
Journal:  Mult Scler       Date:  2007-11       Impact factor: 6.312

10.  Pharmacist intervention to improve medication adherence in heart failure: a randomized trial.

Authors:  Michael D Murray; James Young; Shawn Hoke; Wanzhu Tu; Michael Weiner; Daniel Morrow; Kevin T Stroupe; Jingwei Wu; Daniel Clark; Faye Smith; Irmina Gradus-Pizlo; Morris Weinberger; D Craig Brater
Journal:  Ann Intern Med       Date:  2007-05-15       Impact factor: 25.391

View more
  60 in total

1.  Adherence to first-line disease-modifying therapy for multiple sclerosis in kuwait.

Authors:  Raed Alroughani; Anil Thussu
Journal:  Int J MS Care       Date:  2012

2.  Injectable multiple sclerosis medications: a patient survey of factors associated with injection-site reactions.

Authors:  Thomas M Stewart; Zung Vu Tran
Journal:  Int J MS Care       Date:  2012

3.  The evolving role of the multiple sclerosis nurse: an international perspective.

Authors:  Therese Burke; Sara Dishon; Lynn McEwan; Jennifer Smrtka
Journal:  Int J MS Care       Date:  2011

4.  Walgreens connected care: impact of managed therapy on adherence to medications used to treat multiple sclerosis and related comorbid conditions.

Authors:  Janeen DuChane; Bobby Clark; Francis Staskon; Rick Miller; Kathleen Love; Ian Duncan
Journal:  Int J MS Care       Date:  2015 Mar-Apr

5.  Pegylated interferon beta-1a (Plegridy) Italian real-world experience: a Delphi analysis of injection-site reaction and flu-like symptom management.

Authors:  Cinzia Cordioli; Graziella Callari; Roberta Fantozzi; Francesca Caruso; Giuseppe Martucci; Santa Mascara; Valentina Zipoli
Journal:  Neurol Sci       Date:  2021-01-13       Impact factor: 3.307

6.  Management Strategies for Flu-Like Symptoms and Injection-Site Reactions Associated with Peginterferon Beta-1a: Obtaining Recommendations Using the Delphi Technique.

Authors:  June Halper; Diego Centonze; Scott D Newsome; DeRen Huang; Christopher Robertson; Xiaojun You; Guido Sabatella; Vladimir Evilevitch; Leslie Leahy
Journal:  Int J MS Care       Date:  2016 Jul-Aug

7.  Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study.

Authors:  Bernard Uitdehaag; Cris Constantinescu; Peter Cornelisse; Douglas Jeffery; Ludwig Kappos; David Li; Magnhild Sandberg-Wollheim; Anthony Traboulsee; Elisabetta Verdun; Victor Rivera
Journal:  Ther Adv Neurol Disord       Date:  2011-01       Impact factor: 6.570

8.  Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis.

Authors:  Kenneth P Johnson
Journal:  Ther Clin Risk Manag       Date:  2010-04-15       Impact factor: 2.423

9.  Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey.

Authors:  Rocco Haase; Jennifer S Kullmann; Tjalf Ziemssen
Journal:  Ther Adv Neurol Disord       Date:  2016-03-15       Impact factor: 6.570

10.  Impact of fampridine on quality of life: clinical benefit in real-world practice.

Authors:  María Belén Marzal-Alfaro; María Luisa Martín Barbero; JoseM García Domínguez; Fernando Romero-Delgado; María Luisa Martínez Ginés; Ana Herranz; María Sanjurjo-Sáez
Journal:  Eur J Hosp Pharm       Date:  2017-01-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.